Abstract
While a substantial proportion of adults infected with SARS-CoV-2 progress to develop severe disease, children rarely manifest respiratory complications. Therefore, understanding differences in the local and systemic response to SARS-CoV-2 infection between children and adults may provide important clues about the pathogenesis of SARS-CoV-2 infection. To address this, we first generated a healthy reference multi-omics single cell data set from children (n=30) in whom we have profiled triple matched samples: nasal and tracheal brushings and PBMCs, where we track the developmental changes for 42 airway and 31 blood cell populations from infancy, through childhood to adolescence. This has revealed the presence of naive B and T lymphocytes in neonates and infants with a unique gene expression signature bearing hallmarks of innate immunity. We then contrast the healthy reference with equivalent data from severe paediatric and adult COVID-19 patients (total n=27), from the same three types of samples: upper and lower airways and blood. We found striking differences: children with COVID-19 as opposed to adults had a higher proportion of innate lymphoid and non-clonally expanded naive T cells in peripheral blood, and a limited interferon-response signature. In the airway epithelium, we found the highest viral load in goblet and ciliated cells and describe a novel inflammatory epithelial cell population. These cells represent a transitional regenerative state between secretory and ciliated cells; they were found in healthy children and were enriched in paediatric and adult COVID-19 patients. Epithelial cells display an antiviral and neutrophil-recruiting gene signature that is weaker in severe paediatric versus adult COVID-19. Our matched blood and airway samples allowed us to study the spatial dynamics of infection. Lastly, we provide a user-friendly interface for this data1 as a highly granular reference for the study of immune responses in airways and blood in children.
Competing Interest Statement
S.A.T. has received remunerations for consulting and Scientific Advisory Board work from Genentech, Biogen, Roche and GlaxoSmithKline as well as Foresite Labs over the past three years. P.M. is a Medical Research Council-GlaxoSmithKline (MRC-GSK) Experimental Medicine Initiative to Explore New Therapies (EMINENT) clinical training fellow with project funding, has served on an advisory board for SOBI, outside the submitted work, and receives co-funding by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (UCLH BRC).
Funding Statement
We acknowledge funding from the Chan Zuckerberg Initiative (grant 2017-174169) and from Wellcome (WT211276/Z/18/Z and Sanger core grant WT206194). M.Z.N, S.M.J and K.B.M have been funded by the Rosetrees Trust (M944, M35F2) and from Action Medical Research (GN2911). The project has received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 874656. M.Z.N. acknowledges funding from the Rutherford Fund Fellowship allocated by the MRC, and M.Z.N. and S.M.J. from the UK Regenerative Medicine Platform 2 (MR/5005579/1), the Longfonds BREATH consortium and University College London Hospitals Biomedical Research Centre. M.Y. is funded by The Jikei University School of Medicine. KBW acknowledges funding from University College London, Birkbeck MRC Doctoral Training Programme. S.S. was supported by a Japan Society for the Promotion of Science Overseas Fellowship (310072). R.G.W. was supported by NIH grant U19AI135964 and a GlaxoSmithKline Distinguished Scholar in Respiratory Health grant from the CHEST Foundation. A.V.M. was supported by NIH grant U19AI135964.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was given through the Living Airway Biobank, administered through UCL Great Ormond Street Institute of Child Health (REC reference: 19/NW/0171, IRAS project ID 261511, North West - Liverpool East Research Ethics Committee), REC reference 18/SC/0514 (IRAS project 245471, South Central - Hampshire B Research Ethics Committee) administered through University College London Hospitals NHS Foundation Trust and REC reference 18/EE/0150 (IRAS project ID 236570, East of England - Cambridge Central Research Ethics Committee) administered through Great Ormond Street Hospital NHS Foundation Trust, as well as by the local R&D departments at all hospitals. Ethical approval for sample collection from patients with severe pneumonia was given by Northwestern Institutional Review Board, study STU00204868 (PI Richard Wunderink).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data set from our study can be explored interactively through a web portal: https://covid19cellatlas.org. The data object, as a h5ad file, can also be downloaded from the portal page. The processed data will be available for download from Array Express. Counts matrices from bronchial brushings obtained from patients at Northwestern Memorial Hospital, Chicago, are available at GEO, accession number GSE168215.
